A/Prof Philip Thompson
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
240 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
DOI: 10.1158/2643-3230.BCD-25-03452026
Journal article
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.
DOI: 10.1182/bloodadvances.20260202432026
Journal article
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma
DOI: 10.1182/bloodadvances.20250185462026
Journal article
Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effective.
DOI: 10.1182/bloodadvances.20260198712026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Balancing gains and pains: infections in the bispecific era
DOI: 10.1080/10428194.2025.25860822025
Journal article
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
DOI: 10.1038/s41408-025-01236-6
RECENT SCHOLARLY WORKS
2025
Journal article
Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor lenalidomide [LEN]) and 2C (epcor R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial
DOI: 10.1182/blood-2025-10152025
Conference Proceedings
Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.
DOI: 10.1182/blood-2025-27792025
Journal article
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
DOI: 10.1200/JCO-25-01695